Hazards of antithrombotic therapy on hemodialysis patients with atrial fibrillation and high thromboembolic risk

A Taiwanese population-based cohort study

Yu Hsien Lai, Tsung Cheng Hsieh, Chu Lin Chou, Chiu Huang Kuo, Yu Li Lin, Chih Hsien Wang, Te Chao Fang

Research output: Contribution to journalArticle

Abstract

The benefit of antithrombotic therapy in hemodialysis (HD) patients with atrial fibrillation (AF) and high thromboembolic risk has not been proved. The purpose of this study was to examine the effects of antithrombotic therapy on HD patients with AF and high thromboembolic risk. We analysed the outcomes of 1,197 HD patients with AF having CHA2DS2-VASc scores ≥ 2 points by using data retrieved from the National Health Insurance Research Database between 1997 and 2008. Four groups of patients, namely aspirin, warfarin, aspirin combined with warfarin, and non-treatment groups, were compared. Between the treatment and non-treatment groups, multivariate Cox proportional analysis revealed no significant difference in the mortality. Among the treatment groups, the aspirin combined with warfarin group had a higher mortality than that of the aspirin group. No significant differences were observed among the four groups in the risks of haemorrhagic stroke, gastrointestinal bleeding, congestive heart failure, acute coronary syndrome, and peripheral arterial occlusive disease. However, the risk of ischemic stroke was significantly higher in the aspirin and the aspirin combined with warfarin groups than in the non-treatment group. In HD patients with AF and with high thromboembolic risks, the mortality rate was not significantly different between treatment groups and non-treatment group. However, the risk of ischemic stroke was significantly higher in aspirin and aspirin plus warfarin groups when compared with non-treatment group. Therefore, the usage of aspirin and warfarin in these patients should be meticulously evaluated.

Original languageEnglish
Article numberIJCEM0053331
Pages (from-to)13982-13991
Number of pages10
JournalInternational Journal of Clinical and Experimental Medicine
Volume10
Issue number9
Publication statusPublished - Sep 30 2017

Fingerprint

Atrial Fibrillation
Aspirin
Renal Dialysis
Hazards
Cohort Studies
Warfarin
Population
Therapeutics
Stroke
Mortality
Health insurance
Arterial Occlusive Diseases
Peripheral Arterial Disease
National Health Programs
Acute Coronary Syndrome
Heart Failure
Databases
Hemorrhage
Research

Keywords

  • Anticoagulation therapy
  • Aspirin
  • Atrial fibrillation
  • Hemodialysis
  • Warfarin

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Hazards of antithrombotic therapy on hemodialysis patients with atrial fibrillation and high thromboembolic risk : A Taiwanese population-based cohort study. / Lai, Yu Hsien; Hsieh, Tsung Cheng; Chou, Chu Lin; Kuo, Chiu Huang; Lin, Yu Li; Wang, Chih Hsien; Fang, Te Chao.

In: International Journal of Clinical and Experimental Medicine, Vol. 10, No. 9, IJCEM0053331, 30.09.2017, p. 13982-13991.

Research output: Contribution to journalArticle

@article{4cff36cd6beb48da90b2ee6ad6a76ccc,
title = "Hazards of antithrombotic therapy on hemodialysis patients with atrial fibrillation and high thromboembolic risk: A Taiwanese population-based cohort study",
abstract = "The benefit of antithrombotic therapy in hemodialysis (HD) patients with atrial fibrillation (AF) and high thromboembolic risk has not been proved. The purpose of this study was to examine the effects of antithrombotic therapy on HD patients with AF and high thromboembolic risk. We analysed the outcomes of 1,197 HD patients with AF having CHA2DS2-VASc scores ≥ 2 points by using data retrieved from the National Health Insurance Research Database between 1997 and 2008. Four groups of patients, namely aspirin, warfarin, aspirin combined with warfarin, and non-treatment groups, were compared. Between the treatment and non-treatment groups, multivariate Cox proportional analysis revealed no significant difference in the mortality. Among the treatment groups, the aspirin combined with warfarin group had a higher mortality than that of the aspirin group. No significant differences were observed among the four groups in the risks of haemorrhagic stroke, gastrointestinal bleeding, congestive heart failure, acute coronary syndrome, and peripheral arterial occlusive disease. However, the risk of ischemic stroke was significantly higher in the aspirin and the aspirin combined with warfarin groups than in the non-treatment group. In HD patients with AF and with high thromboembolic risks, the mortality rate was not significantly different between treatment groups and non-treatment group. However, the risk of ischemic stroke was significantly higher in aspirin and aspirin plus warfarin groups when compared with non-treatment group. Therefore, the usage of aspirin and warfarin in these patients should be meticulously evaluated.",
keywords = "Anticoagulation therapy, Aspirin, Atrial fibrillation, Hemodialysis, Warfarin",
author = "Lai, {Yu Hsien} and Hsieh, {Tsung Cheng} and Chou, {Chu Lin} and Kuo, {Chiu Huang} and Lin, {Yu Li} and Wang, {Chih Hsien} and Fang, {Te Chao}",
year = "2017",
month = "9",
day = "30",
language = "English",
volume = "10",
pages = "13982--13991",
journal = "International Journal of Clinical and Experimental Medicine",
issn = "1940-5901",
publisher = "e-Century Publishing Corporation",
number = "9",

}

TY - JOUR

T1 - Hazards of antithrombotic therapy on hemodialysis patients with atrial fibrillation and high thromboembolic risk

T2 - A Taiwanese population-based cohort study

AU - Lai, Yu Hsien

AU - Hsieh, Tsung Cheng

AU - Chou, Chu Lin

AU - Kuo, Chiu Huang

AU - Lin, Yu Li

AU - Wang, Chih Hsien

AU - Fang, Te Chao

PY - 2017/9/30

Y1 - 2017/9/30

N2 - The benefit of antithrombotic therapy in hemodialysis (HD) patients with atrial fibrillation (AF) and high thromboembolic risk has not been proved. The purpose of this study was to examine the effects of antithrombotic therapy on HD patients with AF and high thromboembolic risk. We analysed the outcomes of 1,197 HD patients with AF having CHA2DS2-VASc scores ≥ 2 points by using data retrieved from the National Health Insurance Research Database between 1997 and 2008. Four groups of patients, namely aspirin, warfarin, aspirin combined with warfarin, and non-treatment groups, were compared. Between the treatment and non-treatment groups, multivariate Cox proportional analysis revealed no significant difference in the mortality. Among the treatment groups, the aspirin combined with warfarin group had a higher mortality than that of the aspirin group. No significant differences were observed among the four groups in the risks of haemorrhagic stroke, gastrointestinal bleeding, congestive heart failure, acute coronary syndrome, and peripheral arterial occlusive disease. However, the risk of ischemic stroke was significantly higher in the aspirin and the aspirin combined with warfarin groups than in the non-treatment group. In HD patients with AF and with high thromboembolic risks, the mortality rate was not significantly different between treatment groups and non-treatment group. However, the risk of ischemic stroke was significantly higher in aspirin and aspirin plus warfarin groups when compared with non-treatment group. Therefore, the usage of aspirin and warfarin in these patients should be meticulously evaluated.

AB - The benefit of antithrombotic therapy in hemodialysis (HD) patients with atrial fibrillation (AF) and high thromboembolic risk has not been proved. The purpose of this study was to examine the effects of antithrombotic therapy on HD patients with AF and high thromboembolic risk. We analysed the outcomes of 1,197 HD patients with AF having CHA2DS2-VASc scores ≥ 2 points by using data retrieved from the National Health Insurance Research Database between 1997 and 2008. Four groups of patients, namely aspirin, warfarin, aspirin combined with warfarin, and non-treatment groups, were compared. Between the treatment and non-treatment groups, multivariate Cox proportional analysis revealed no significant difference in the mortality. Among the treatment groups, the aspirin combined with warfarin group had a higher mortality than that of the aspirin group. No significant differences were observed among the four groups in the risks of haemorrhagic stroke, gastrointestinal bleeding, congestive heart failure, acute coronary syndrome, and peripheral arterial occlusive disease. However, the risk of ischemic stroke was significantly higher in the aspirin and the aspirin combined with warfarin groups than in the non-treatment group. In HD patients with AF and with high thromboembolic risks, the mortality rate was not significantly different between treatment groups and non-treatment group. However, the risk of ischemic stroke was significantly higher in aspirin and aspirin plus warfarin groups when compared with non-treatment group. Therefore, the usage of aspirin and warfarin in these patients should be meticulously evaluated.

KW - Anticoagulation therapy

KW - Aspirin

KW - Atrial fibrillation

KW - Hemodialysis

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=85030634471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030634471&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 13982

EP - 13991

JO - International Journal of Clinical and Experimental Medicine

JF - International Journal of Clinical and Experimental Medicine

SN - 1940-5901

IS - 9

M1 - IJCEM0053331

ER -